

S4 Table. Subgroup who underwent surgery and MLND in no endosonography group vs. in endosonography first group

Subject	Model	Overall survival		
		HR	95% CI	p-value
Histologic type				
Adenocarcinoma	Before PSM (n=91 vs. 168)			
	Unadjusted	0.65	0.39-1.10	0.111
Others	After PSM (n=91 vs. 85)	0.48	0.24-0.97	0.040
	Before PSM (n=109 vs. 105)			
	Unadjusted	0.80	0.49-1.32	0.381
	After PSM (n=93 vs. 70)	0.84	0.46-1.54	0.571
Spatial location				
Central	Before PSM (n=91 vs. 142)			
	Unadjusted	0.55	0.33-0.91	0.019
Peripheral	After PSM (n=80 vs. 88)	0.49	0.26-0.92	0.025
	Before PSM (n=109 vs. 131)			
	Unadjusted	0.86	0.51-1.43	0.551
	After PSM (n=104 vs. 67)	0.84	0.43-1.64	0.618
Tumor attenuation				
Solid	Before PSM (n=185 vs. 249)			
	Unadjusted	0.68	0.47-0.97	0.036
Part-solid	After PSM (n=169 vs. 143)	0.62	0.39-0.99	0.046
	Before PSM (n=15 vs. 24)			
	Unadjusted	0.95	0.68-1.31	0.743
	After PSM (n=15 vs. 12)	0.95	0.68-1.31	0.743

Matching with age, sex, body mass index, smoking status, underlying pulmonary disease, underlying extra-pulmonary comorbidities, clinical T category, and histologic type. CI, confidence interval; HR, hazard ratio; MLND, mediastinal lymph nodes dissection; PSM, propensity score matching.